Market Overview

UPDATE: Burrill Initiates Sangamo Biosciences at Market Outperform

Related SGMO
Is Sangamo The Next Biotech Stock To Break Out?
Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms

Burrill initiated coverage on Sangamo Biosciences (NASDAQ: SGMO) with a Market Outperform rating and a $28.00 price target.

Burrill noted, "We believe Sangamo's innovative genome editing approach could provide novel and transformative therapeutics, which could revolutionize the treatment of genetic disorders. … We believe there is a significant upside to our valuation, given the additional opportunities embedded in the platform, not to mention ex-U.S. markets, which aren't included in our calculation."

Sangamo Biosciences closed at $8.82 on Friday.

Latest Ratings for SGMO

DateFirmActionFromTo
Sep 2014JefferiesInitiates Coverage onBuy
Aug 2014JP MorganInitiates Coverage onOverweight
Jun 2013Cowen & CompanyInitiates Coverage onOutperform

View More Analyst Ratings for SGMO
View the Latest Analyst Ratings

Posted-In: BurrillAnalyst Color Initiation Analyst Ratings

 

Related Articles (SGMO)

Around the Web, We're Loving...

Get Benzinga's Newsletters